"ADHD Medication Recall Update: FDA Completes Nationwide Bottle Recall"

"ADHD Medication Recall Update: FDA Completes Nationwide Bottle Recall"

Quick read below — save or share if useful.

A Nationwide Recall of 8,500 ADHD Medication Bottles Just Received an Update from the FDA

Attention-deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental disorder that affects millions of individuals in the United States. While the condition is often associated with children, there has been a notable increase in ADHD diagnoses among adults in recent years. According to data from healthcare technology company Truveta, first-time diagnoses for adults between the ages of 30 and 64 have seen a significant uptick since 2021.

For individuals whose daily functions are impacted by ADHD, medication can be a crucial tool in managing symptoms. However, a recent development in the pharmaceutical industry has brought attention to the importance of vigilance when it comes to medication safety.

On August 26, 2025, the U.S. Food and Drug Administration (FDA) announced a voluntary recall of 8,544 bottles of Lisdexamfetamine Dimesylate by pharmaceutical company Lannett Company, LLC. The recall was initiated due to a label mix-up, where a bottle labeled as containing Lisdexamphetamine Dimesylate Capsules 40mg actually contained capsules of 30mg strength. This medication, distributed nationwide, is commonly used to treat ADHD symptoms in individuals aged 6 and older.

Subsequent to the initial recall announcement, the FDA provided an update on January 13, indicating that the recall has now been completed. This means that the necessary actions to address the labeling issue have been carried out by the pharmaceutical company.

Lisdexamfetamine Dimesylate is classified as a central nervous system (CNS) stimulant and is known to enhance attention and reduce restlessness in patients with ADHD. Additionally, this medication can be prescribed for the treatment of moderate to severe binge eating disorder. Sold under the brand names Arynta and Vyvanse in the U.S., Lisdexamfetamine Dimesylate is a commonly prescribed drug for ADHD management.

The recall applies specifically to Lisdexamfetamine Dimesylate Capsules, 40 milligrams, in 100-count bottles with lot number 25280726A and expiration date 03/2027. These bottles were distributed by Lannett Company, Inc., based in Philadelphia, PA.

Classified as a Class II event as of August 25, 2025, the recall indicates that while exposure to the affected product could lead to reversible adverse health effects, the likelihood of such effects occurring is considered to be low.

Recognizing the widespread impact of ADHD across all age groups, it is crucial for individuals receiving treatment to have access to safe and effective medications. With this recent recall serving as a reminder of the importance of medication safety, patients and healthcare providers must remain vigilant in ensuring the integrity and accuracy of prescribed medications.

Conclusion

As the prevalence of ADHD continues to rise, it is imperative for individuals with the condition to have access to reliable and safe treatment options. The recent recall of 8,500 bottles of ADHD medication highlights the importance of thorough quality control measures in the pharmaceutical industry and the need for ongoing vigilance in medication safety. By staying informed and proactive in addressing medication-related issues, patients and healthcare providers can work together to ensure the well-being of those affected by ADHD.

Follow & Connect
Explore My Other Blogs

Enjoyed this post? Share it or explore more across my blogs and channels.

Hi, I’m Ciro Irmici, an entrepreneur and investor from San Severo, Italy. My passions range from investments (stocks, crypto, dividends) to automation and creating businesses that help people. I believe in building things that matter, like a gym for all and a theatre for people to enjoy music. I love learning and sharing what I learn: how to create eBooks, audiobooks, and other digital products. I’m also deeply into fitness (gym, running, jump rope) and creativity (painting, music, design). My ultimate goal? To reach financial freedom and help others achieve their dreams.

Comments

Post a Comment